ClinicalTrials.gg
CompletedNCT04296890SORAYAUpdated Aug 7, 2024Results posted

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

A Phase 3 interventional study of Mirvetuximab Soravtansine in Epithelial Ovarian Cancer, Peritoneal Cancer and Fallopian Tube Cancer, sponsored by ImmunoGen, Inc.. Completed at 89 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-07.

Sponsored by ImmunoGen, Inc. (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States — 29 open to participants now, 50 under way, 8 of them phase 3. Carcinoma, Ovarian Epithelial · United States.

Enrollment
74th of 381
106 · median 35
Started
2020
with 8 others
Phase 3
37 of 500
5 open now
Registered
433rd of 500
by date

Among the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, this one is the 74th largest by enrollment of the 381 interventional ones that give a count, is one of 9 that started in 2020, is one of 37 in phase 3, and was the 433rd registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

29 of the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, or all of them as a file.
02

Study summary

This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in participants with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate Receptor-Alpha (FRα). Participants will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. All participants will receive single-agent MIRV at 6 mg/kg adjusted ideal body weight administered on Day 1 of every 3-week cycle.

Read the detailed description

This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in participants with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate Receptor Alpha (FRα). Participants will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. FRα positivity will be defined by the Ventana FOLR1 (Folate Receptor 1/Folate Receptor Alpha) Assay.

Approximately 110 eligible participants will be enrolled to achieve a total of 105 efficacy evaluable participants. Efficacy evaluable participants include those who have measurable lesions per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) at baseline and received at least 1 dose of MIRV.

All participants will receive single-agent MIRV at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).

Tumor response will be evaluated by the Investigator using RECIST v1.1. Computerized tomography (CT) or magnetic resonance imaging (MRI) scans will be collected for sensitivity analysis by blinded independent central review (BICR).

Participants will continue to receive MIRV until disease progression, unacceptable toxicity, withdrawal of consent, death, or until the Sponsor terminates the study (whichever comes first).

Tumor assessments, including radiological assessments by CT/MRI scans will be performed at Screening and subsequently every 6 weeks (± 1 week) from Cycle 1 Day 1 (C1D1) for the first 36 weeks then every 12 weeks (± 3 weeks) until disease progression, death, the start of new anticancer therapy, or participant's withdrawal of consent (whichever occurs first).

Participants who discontinue MIRV for reasons other than progressive disease (PD) will continue with tumor assessments until documentation of PD or the start of a new anticancer therapy, whichever comes first. Prior to Week 36 (from Cycle 1, Day 1), assessments should occur every 6 weeks (± 1 week) as allowed by local requirements but must occur at an interval of no more than 12 weeks. After Week 36, assessment will occur every 12 weeks (± 3 weeks) until documentation of PD or the start of new anticancer therapy.

All participants who discontinue MIRV will be followed for survival every 3 months (± 1 month) until death, lost to follow-up, withdrawal of consent for survival follow-up, or end of study (EOS) (whichever comes first). Additional survival follow-up calls may occur periodically, if needed.

03

Conditions studied

  • Epithelial Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer

Keywords

  • Platinum resistant
  • Folate-receptor alpha expression
  • Phase 3
  • Antibody-drug conjugate
  • mirvetuximab soravtansine
  • IMGN853
  • Epithelial Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer
  • MIRV
  • FRα
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female participants ≥ 18 years of age
  2. Participants must have a confirmed diagnosis of high-grade serous epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer
  3. Participants must have platinum-resistant disease:

    1. Participants who have only had 1 line of platinum based therapy must have received at least 4 cycles of platinum, must have had a response (complete response/remission [CR] or partial response/remission [PR]) and then progressed between > 3 months and ≤ 6 months after the date of the last dose of platinum
    2. Participants who have received 2 or 3 lines of platinum therapy must have progressed on or within 6 months after the date of the last dose of platinum

    Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression

    Note: Participants who are platinum during front-line treatment are excluded (see exclusion criteria)

  4. Participants must have progressed radiographically on or after their most recent line of anticancer therapy.
  5. Participants must be willing to provide an block or slides, or undergo procedure to obtain a new biopsy using a low-risk, medically routine procedure for immunohistochemistry (IHC) confirmation of Folate Receptor α (FRα) positivity
  6. Participant's tumor must be positive for FRα expression as defined by the Ventana FOLR1 Assay
  7. Participants must have at least 1 lesion that meets the definition of by v1.1 (radiologically measured by the Investigator)
  8. Participants must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, including at least 1 containing bevacizumab, and for whom single-agent therapy is appropriate as the next line of treatment:

    1. Adjuvant ± considered 1 line of therapy
    2. Maintenance therapy (e.g., bevacizumab, poly adenosine diphosphate-ribose polymerase (PARP) inhibitors) will be considered part of the preceding line of therapy (i.e., not counted independently)
    3. Therapy changed due to toxicity in the absence of progression will be considered part of the same line (i.e., not counted independently)
    4. Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance
  9. Participants must have an Performance Status (ECOG PS) of 0 or 1
  10. Participants must have completed prior therapy within the specified times below:

    1. Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to first dose of MIRV
    2. Focal radiation completed at least 2 weeks prior to first dose of MIRV
  11. Participants must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities (except alopecia)
  12. Participants must have completed any major surgery at least 4 weeks prior to first dose of MIRV and have recovered or stabilized from the side effects of prior surgery
  13. Participants must have adequate hematologic, liver and kidney functions defined as:

    1. (ANC) ≥ 1.5 x 10\^9/L (1,500/μL) without G-CSF in the prior 10 days or long-acting WBC growth factors in the prior 20 days
    2. count ≥ 100 x 10\^9/L (100,000/μL) without platelet transfusion in the prior 10 days
    3. ≥ 9.0 g/dL without packed red blood cell (PRBC) transfusion in the prior 21 days
    4. Serum creatinine ≤ 1.5 x (ULN)
    5. (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN
    6. Serum ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin \< 3.0 x ULN)
    7. Serum albumin ≥ 2 g/dL
  14. Participants or their legally authorized representative must be willing and able to sign the form (ICF) and to adhere to the protocol requirements
  15. Women of (WCBP) must agree to use highly effective method(s) while on MIRV and for at least 3 months after the last dose
  16. WCBP must have a negative pregnancy test within the 4 days prior to the first dose of MIRV

Exclusion criteria

Exclusion Criteria:

  1. Male participants
  2. Participants with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade/borderline ovarian tumor
  3. Participants with primary platinum- disease, defined as disease that did not respond to (CR or PR) or has progressed within 3 months of the last dose of platinum-containing chemotherapy
  4. Participants with prior wide-field radiotherapy (RT) affecting at least 20 percent of the bone marrow
  5. Participants with > Grade 1 peripheral neuropathy per (CTCAE)
  6. Participants with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision
  7. Participants with serious concurrent illness or active infection, including, but not limited to the following:

    1. Active or C infection (whether or not on active antiviral therapy)
    2. (HIV) infection
    3. Active cytomegalovirus infection
    4. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of MIRV

    Note: Testing at screening is not required for the above infections unless clinically indicated

  8. Participants with a history of multiple sclerosis (MS) or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome)
  9. Participants with clinically significant cardiac disease including, but not limited to, any of the following:

    1. Myocardial infarction ≤ 6 months prior to first dose
    2. Unstable angina pectoris
    3. Uncontrolled congestive heart failure ( > class II)
    4. Uncontrolled ≥ Grade 3 hypertension (per CTCAE)
    5. Uncontrolled cardiac arrhythmias
  10. Participants with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment
  11. Participants with a history of cirrhotic liver disease ( Class B or C)
  12. Participants with a previous clinical diagnosis of noninfectious interstitial lung disease (ILD), including noninfectious pneumonitis
  13. Participants requiring use of folate-containing supplements (eg, folate deficiency)
  14. Participants with prior to monoclonal antibodies (mAb)
  15. Women who are pregnant or breastfeeding
  16. Participants who received prior treatment with MIRV or other FRα-targeting agents
  17. Participants with untreated or symptomatic central nervous system (CNS)
  18. Participants with a history of other within 3 years prior to enrollment.

    Note: Participants with tumors with a negligible risk for metastasis or death (eg, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible

  19. Prior known hypersensitivity reactions to study drugs and/or any of their
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Treatment

    All participants will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).

    Drug: Mirvetuximab Soravtansine

Interventions

  • Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.

    Also known as: IMGN853, MIRV

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    ORR was defined as percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR: At least 30% decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.

    Time frame: Up to approximately 15 months

Secondary outcomes

  1. Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1

    DOR was defined as the time from the date of the first response (CR or PR), until the date of progressive disease (PD) or death from any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was estimated using the Kaplan-Meier method.

    Time frame: Up to approximately 15 months

  2. Percentage of Participants With CA-125 Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria

    The GCIG CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. The response must have been confirmed and maintained for at least 28 days.

    Time frame: Up to approximately 15 months

  3. Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1

    PFS was defined as the time from initiation of study drug until the date of PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: Up to approximately 15 months

  4. Overall Survival Assessed by the Investigator Using RECIST v1.1

    Overall survival was defined as the time from the date of first dose until the date of death from any cause, estimated using the Kaplan-Meier method.

    Time frame: Up to approximately 27 months

  5. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. TEAEs were defined as AEs with an onset date on or after the first dose of Study drug, and within 30 days of the last dose of study drug or prior to the start of a new anticancer treatment, whichever occurred first. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to approximately 27 months

07

Results

Posted Aug 7, 2024

Participant flow

Participant flow — Overall Study
MilestoneMirvetuximab Soravtansine
Started106
Inv efficacy evaluable population105
Completed38
Not completed68
Withdrew: Withdrawal by subject1
Withdrew: Death62
Withdrew: Lost to follow-up3
Withdrew: Other than specified2

Outcome measures

PrimaryObjective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

ORR was defined as percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR: At least 30% decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.

Time frame:
Up to approximately 15 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
percentage of participantsMirvetuximab Soravtansine
Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)32.4 (23.6 to 42.2)
SecondaryDuration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1

DOR was defined as the time from the date of the first response (CR or PR), until the date of progressive disease (PD) or death from any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was estimated using the Kaplan-Meier method.

Time frame:
Up to approximately 15 months
Reported as:
Median · months
Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1
monthsMirvetuximab Soravtansine
Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.16.93 (5.55 to 9.66)
SecondaryPercentage of Participants With CA-125 Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria

The GCIG CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. The response must have been confirmed and maintained for at least 28 days.

Time frame:
Up to approximately 15 months
Reported as:
Number · percentage of participants
Percentage of Participants With CA-125 Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria
percentage of participantsMirvetuximab Soravtansine
Percentage of Participants With CA-125 Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria46.5 (35.7 to 57.6)
SecondaryProgression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1

PFS was defined as the time from initiation of study drug until the date of PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
Up to approximately 15 months
Reported as:
Median · months
Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1
monthsMirvetuximab Soravtansine
Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.14.27 (3.71 to 5.22)
SecondaryOverall Survival Assessed by the Investigator Using RECIST v1.1

Overall survival was defined as the time from the date of first dose until the date of death from any cause, estimated using the Kaplan-Meier method.

Time frame:
Up to approximately 27 months
Reported as:
Median · months
Overall Survival Assessed by the Investigator Using RECIST v1.1
monthsMirvetuximab Soravtansine
Overall Survival Assessed by the Investigator Using RECIST v1.115.0 (11.5 to 18.7)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. TEAEs were defined as AEs with an onset date on or after the first dose of Study drug, and within 30 days of the last dose of study drug or prior to the start of a new anticancer treatment, whichever occurred first. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to approximately 27 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsMirvetuximab Soravtansine
Number of Participants With Treatment-emergent Adverse Events (TEAEs)105

Adverse events

Collected over Up to approximately 27 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mirvetuximab Soravtansine62/106 (58.5%)36/106 (34%)102/106 (96.2%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventMirvetuximab Soravtansine
AscitesGastrointestinal disorders5/106
Small intestinal obstructionGastrointestinal disorders5/106
Pleural effusionRespiratory, thoracic and mediastinal disorders2/106
PneumonitisRespiratory, thoracic and mediastinal disorders2/106
Intestinal obstructionGastrointestinal disorders2/106
Large intestinal obstructionGastrointestinal disorders2/106
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/106
VasculitisVascular disorders1/106
Administration site extravasationGeneral disorders1/106
Disease progressionGeneral disorders1/106
Most frequent other events
Showing 10 of 43
Most frequent other events
EventMirvetuximab Soravtansine
Vision blurredEye disorders49/106
NauseaGastrointestinal disorders41/106
KeratopathyEye disorders34/106
DiarrhoeaGastrointestinal disorders33/106
FatigueGeneral disorders32/106
ConstipationGastrointestinal disorders32/106
Dry eyeEye disorders30/106
Abdominal painGastrointestinal disorders26/106
AstheniaGeneral disorders22/106
CataractEye disorders21/106

Baseline characteristics

The Safety population was defined as participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Mirvetuximab Soravtansine
Mean62 ± 10
Sex: Female, Male
Sex: Female, Male(Participants)Mirvetuximab Soravtansine
Female106
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Mirvetuximab Soravtansine
Hispanic or Latino2
Not Hispanic or Latino99
Unknown or Not Reported5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mirvetuximab Soravtansine
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White102
More than one race0
Unknown or Not Reported2
08

Study locations

89 sites
  • Arizona Oncology Associates
    Phoenix, Arizona 85016, United States
  • City of Hope Medical Center
    Duarte, California 91010, United States
  • California Cancer Associates (cCARE)
    Fresno, California 93720, United States
  • Stanford School of Medicine
    Palo Alto, California 94394, United States
  • California Pacific Medical Center Research Institute
    San Francisco, California 94109, United States
  • Rocky Mountain Cancer Centers
    Littleton, Colorado 80120, United States
  • Sarasota Memorial Health Care System
    Sarasota, Florida 34239, United States
  • Florida Cancer Specialists Panhandle
    Tallahassee, Florida 32308, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Florida Cancer Specialists Research
    West Palm Beach, Florida 33401, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • Hinsdale Hospital
    Hinsdale, Illinois 60521, United States
  • St. Vincent Gynecologic Oncology
    Indianapolis, Indiana 46260, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40207, United States
  • Women's Cancer Center
    Covington, Louisiana 70433, United States
  • Maryland Oncology Hematology, P.A.
    Rockville, Maryland 20850, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Midwest Oncology Associates/Sarah Cannon
    Kansas City, Missouri 64132, United States
  • Center of Hope at Renown Medical Center
    Reno, Nevada 89502, United States
  • Holy Name Medical Center
    Teaneck, New Jersey 07666, United States
  • Mount Sinai Health System
    New York, New York 10029, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Sarah Cannon Research Institute / Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Texas Oncology-Austin Central
    Austin, Texas 78731, United States
  • Texas Oncology, P.A. - Fort Worth Cancer Center
    Fort Worth, Texas 76104, United States
  • Texas Oncology, P.A. - McAllen
    McAllen, Texas 78503, United States
  • Texas Oncology, P.A. - Sugar Land
    Sugar Land, Texas 77479, United States
  • USOR: Texas Oncology - The Woodlands, Gynecologic Oncology
    The Woodlands, Texas 77380, United States
  • Texas Oncology, P.A. - Tyler
    Tyler, Texas 75702, United States
  • Kadlec Clinic Hematology and Oncology
    Kennewick, Washington 99336, United States
  • University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin 53792, United States
  • Froedtert and the Medical College of Wisconsin Department of Obstetrics & Gynecology
    Milwaukee, Wisconsin 53226, United States
  • Royal North Shore Hospital
    St. Leonards, New South Wales 2065, Australia
  • ICON Cancer Care
    Auchenflower, Queensland 4066, Australia
  • Peninsula and South Eastern Haematology & Oncology Group
    Frankston, Victoria 3199, Australia
  • St John of God Subiaco Hospital
    Subiaco, Western Australia 6008, Australia
  • Cliniques Universitaires Saint Luc - lnstitut Roi Albert II
    Brussels, Bruxelles 1200, Belgium
  • Centre Hopsitalier de l'Ardenne
    Libramont, Luxembourg 6800, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU UCL Namur/Site Sainte Elisabeth
    Namur, B5000, Belgium
  • MHAT "Serdika"
    Sofia, 1632, Bulgaria
  • Všeobecná fakultní nemocnice v Praze
    Praha 2, Prague 128 51, Czechia
  • Universitätsmedizin Mannheim
    Mannheim, Baden-Württemberg 68167, Germany
  • UMG Frauenklinik Robert-Koch-Str. 40
    Göttingen, Niedersachsen 37075, Germany
  • KEM
    Essen, 45135, Germany
  • Mater Misericordiae University Hospital
    Dublin, Leinster 7, Ireland
  • St. James's Hospital
    Dublin, Leinster 8, Ireland
  • Cork University Hospital
    Cork, Munster T12 DC4A, Ireland
  • Bon Secours Hospital
    Cork, Munster T12 DV56, Ireland
  • University Hospital Waterford
    Waterford, Munster X91ER8E, Ireland
  • Beaumont Hospital
    Dublin, 9, Ireland
  • Rambam Medical Center
    Haifa, PO Box 9601, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 91031, Israel
  • Hadassah Ein Kerem Medical center
    Jerusalem, POB 12000, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Kaplan Medical Center
    Rehovot, 76100, Israel
  • Ziv Medical Center
    Safed, 13100, Israel
  • Policlinico S. Orsola-Malpighi
    Bologna, 40138, Italy
  • Azienda Socio Santaria Territoriale degli Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Istituto Oncologico Candiolo
    Candiolo, 10060, Italy
  • Ospedale Cannizzaro di Catania
    Catania, 95126, Italy
  • IEO Istituto Europeo di Oncologia
    Milano, 20141, Italy
  • Azienda Ospedaliera Ospedale Niguarda Ca'Granda
    Milano, 20162, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Napoli, 80131, Italy
  • Istituto Nazionale Tumori- G. Pascale
    Napoli, 87100, Italy
  • Ospedale S.Maria della Misericordia
    Perugia, 6129, Italy
  • Fondazione Policlinico Universitario A. Gemelli IRCCS
    Roma, 00168, Italy
  • Specjalistyczna Przychodnia Lekarska Medicus
    Chorzów, Silesia 41-500, Poland
  • Mazurskim Centrum Onkologiiw Olsztynie
    Olsztyn, Warmińsko-Mazurskie 10-228, Poland
  • Instytut Centrum Zdrowia Matki Polki
    Łódź, Łódzkie 93-338, Poland
  • Institut Català d'Oncologia Badalona Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital La Paz
    Madrid, Castellana 28046, Spain
  • Hospital Teresa Herrera - Complejo Hospitalario Universitario A Coruna
    A Coruña, Galicia 15006, Spain
  • Hospital Quirón Dexeus
    Barcelona, 08028, Spain
  • Vall d'Hebron Institute of Oncology
    Barcelona, 08035, Spain
  • lnstitut Catala d' Oncologia L' Hospitalet
    Barcelona, 08908, Spain
  • Hospital Reina Sofia de Cordoba
    Córdoba, 14004, Spain
  • Institut Català d'Oncología de Girona
    Girona, 17007, Spain
  • Clinica Universidad de Navarra
    Madrid, 28027, Spain
  • MD Anderson Cancer Centre
    Madrid, 28033, Spain
  • Hospital Clínico Universitario San Carlos
    Madrid, 28040, Spain
  • Hospital Clinico Universitario Virgen de la Arrixaca
    Murcia, 30120, Spain
  • Corporació Sanitaria Parc Taulí
    Sabadell, 08208, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Instituto Valenciano de Oncologia
    Valencia, 46010, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Nov 2021, 15 months.

Results were first posted in Aug 2024, 2 years 8 months after primary completion. A results delay was requested in Sep 2022.

Of 33 phase 3 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2020
First posted
Mar 5, 2020
StartActual
Jul 23, 2020
Primary completionActual
Nov 16, 2021
CompletionActual
Nov 16, 2022
Results delay requested
Sep 16, 2022
Results first posted
Aug 7, 2024
Last update
Aug 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04296890
Lead sponsor
ImmunoGen, Inc.
Responsible party
Sponsor
First posted
Mar 5, 2020
Start date
Jul 23, 2020
Primary completion
Nov 16, 2021
Completion
Nov 16, 2022
Results posted
Aug 7, 2024
Last update
Aug 7, 2024

Study contacts

Michael Method, MD, MPH, MBA
study director · ImmunoGen, Inc.
Ursula Matulonis, MD
principal investigator · Dana-Farber Cancer Institute
Robert Coleman, MD
principal investigator · The US Oncology Network

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirvetuximab soravtansine

Start the discussion